Retension Pharmaceuticals

Retension Pharmaceuticals is a clinical-stage biotechnology company developing RTN-001 as a treatment for patients with hypertension. RTN-001 is a unique second-generation PDE5 inhibitor that, unlike earlier PDE5 inhibitors used to treat erectile dysfunction, preferentially distributes to cardiovascular tissues. The compound is a potent and selective cGMP modulator that has been studied in multiple clinical trials involving over 265 subjects. It has demonstrated good tolerability and shown promising efficacy in early studies of patients with uncontrolled hypertension, with blood pressure reductions comparable to most established and clinical-stage antihypertensive drugs, as well as a reduction in central blood pressure.